Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b randomized double-blind trial of 14 versus 28 days of inhaled aztreonam in children with cystic fibrosis and new Pseudomonas aeruginosa airway infection
MOH_2017-10-25_000668Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2017
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) and Pseudomonas aeruginosa airway infection comparing AZLI 28 days with AZLI 14 days followed by placebo 14 days (2 arms). Primary endpoint: Eradication of Pseudomonas aeruginosa during the 28-day post-treatment follow-up period. Started Aug 2017; status: active, not recruiting.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa airway infection
Beyond the preview
Go deeper on MOH_2017-10-25_000668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-25_000668.